market analysis

How Community Pharmacies Earn NHS Revenue: The Fee Structure Explained

From £1.29 per dispensed item to £31.82 per New Medicine Service consultation, the NHS fee schedule shapes every aspect of community pharmacy economics.

By PharmSee · · 1 views

Community pharmacy in England is a business built on NHS contract payments. While many pharmacies also generate retail revenue from over-the-counter products and private services, the core of most community pharmacy income comes from a structured fee schedule set by the NHS. Understanding this fee structure is essential for anyone considering pharmacy ownership, evaluating pharmacy performance, or making sense of the revenue figures in NHSBSA dispensing data.

The dispensing fee: £1.29 per item

The foundation of community pharmacy revenue is the dispensing fee — the payment a pharmacy receives for each NHS prescription item dispensed. Under the current Drug Tariff, this fee is approximately £1.29 per item.

To put this in context: a typical active community pharmacy in an English city dispenses somewhere between 5,000 and 15,000 items per month, depending on location, GP proximity, and patient demographics. At £1.29 per item, a pharmacy dispensing 8,000 items monthly generates approximately £10,320 per month — or around £124,000 per year — from dispensing fees alone.

PharmSee's analysis of NHSBSA data across nine English city centres shows average annual dispensing revenue per active pharmacy ranging from approximately £91,000 (Nottingham) to £160,000 (Newcastle for independents). These figures reflect total dispensing-related NHS payments, which include the dispensing fee plus medicine margin and other supplementary payments.

Clinical services: where the higher fees are

Beyond dispensing, community pharmacies can earn significantly higher per-consultation fees through NHS-funded clinical services.

ServiceFeeTypical annual opportunity
New Medicine Service (NMS)£31.82 per consultationUp to £12,000+
Pharmacy First£15.00 per consultationUp to £6,000+
Flu vaccination£11.50 per vaccinationVaries seasonally
COVID vaccinationUp to £20.00 per doseVaries by campaign

The New Medicine Service

The NMS is one of the most valuable clinical services available to community pharmacies. It involves structured follow-up consultations with patients who have been prescribed a new medicine for a long-term condition (such as hypertension, type 2 diabetes, asthma, or COPD). The pharmacist provides two consultations — an initial discussion and a follow-up — to support the patient in understanding and adhering to their new medicine.

At £31.82 per completed service, a pharmacy completing 30 NMS consultations per month would generate approximately £11,455 per year from this single service. The difference between pharmacies that actively identify NMS-eligible patients and those that take a passive approach can be substantial.

Pharmacy First

Launched in February 2024, Pharmacy First pays £15 per clinical consultation for seven specified conditions. A pharmacy conducting 400 Pharmacy First consultations annually would earn approximately £6,000. Active pharmacies in areas with limited GP access may achieve higher volumes.

Vaccinations

Seasonal flu and COVID vaccination campaigns provide periodic income boosts. Flu vaccinations at £11.50 per dose can generate several thousand pounds during the autumn-winter season, depending on patient volume.

Other NHS contract payments

Community pharmacies also receive several supplementary NHS payments:

Establishment payment: A fixed monthly contribution toward pharmacy running costs, paid to all contracted pharmacies.

Practice payment: A fixed monthly payment per pharmacy for maintaining readiness to provide NHS services.

Supplementary and essential service payments: Various additional payments for services including repeat dispensing, discharge medicine service support, and public health campaigns.

These supplementary payments are less variable than dispensing fees and clinical service income, providing a baseline revenue floor for contracted pharmacies.

What the fee structure means for pharmacy economics

The fee structure creates clear economic incentives:

Volume matters for dispensing. At £1.29 per item, dispensing revenue is fundamentally a volume game. Pharmacies with higher GP proximity, more elderly patients (who generate more prescription items per capita), and less competition tend to generate higher dispensing revenue.

Clinical services reward proactive pharmacies. NMS at £31.82 per consultation is worth roughly 25 dispensed items. Pharmacies that invest pharmacist time in identifying and completing NMS consultations can significantly outperform their dispensing-only revenue. This creates a workforce tension: pharmacists conducting NMS and Pharmacy First consultations are not simultaneously available for dispensing, increasing demand for dispensers and pharmacy technicians.

Location is economics. GP-to-pharmacy ratios, local deprivation levels, and population demographics determine the available prescription volume. PharmSee's data shows that cities with higher GP-to-pharmacy ratios (such as Liverpool at 1.42:1 and Plymouth at 1.51:1) tend to support higher per-pharmacy revenue than cities where pharmacies outnumber GP practices (such as Nottingham at 0.75:1).

For pharmacy revenue benchmarking and competitive analysis, visit PharmSee's pharmacy analytics. For location analysis including GP density and deprivation scoring, explore the location analysis tool.

Methodology

Fee figures are based on the current NHS Drug Tariff and published NHS England service specifications. Revenue scenarios are illustrative calculations based on PharmSee's observed dispensing volumes across English cities. Individual pharmacy revenue will vary based on location, services offered, and patient demographics.